Sycamore Networks, Inc. is the developer and marketer of optical networking products for wireline and wireless network service providers, and government entities with private fiber networks. Its networking product portfolio includes optical switching products, network management products. The company’s optical switching products include SN 16000 SC, SN 16000, and SN 3000, which are designed to enable service providers to provide and manage network bandwidth in the metropolitan, regional, and core segments of the optical network. In addition, the company offers related services, such as installation, maintenance, technical assistance, and customer training.

Based in Chelmsford, MA, revenue for the first nine months of fiscal 2006 was $71.1 million, compared with $46.9 million for the first nine months of fiscal 2005. Net income for the first nine months of fiscal 2006 was $22.4 million compared with a net loss of $25.2 million for the first nine months of fiscal 2005.

Daniel E. Smith, Sycamore’s president and chief executive officer said, “During the quarter we grew our revenue sequentially and year-over-year, improved our margin performance, and reduced operating expenses. As a result, we reported operating profitability and another quarter of positive cash generation. We continue to execute on our business strategy and our continued progress, we believe, underscores the unique value our intelligent networking solutions deliver to our customers.”

Biocon India Limited

BSE: BIOCON Chairman and MD: Kiran Mazumdar-Shaw Founded: 1978

Biocon is India’s biggest integrated biotechnology company focused on the development of biopharmaceuticals.

The Bangalore based Biocon went public in 2004 becoming a billion dollar firm on the first day of listing only to fall down later. Together with its subsidiaries Clinigene and Syngene, Biocon employs about 2000 people.
In the financial year 2005-06, the total income of the company increased 9 percent to $180 million while profit after tax was $39 million. Revenues from the biopharmaceuticals and enzymes business grew 6 percent to $156 million contributing 87 percent to operating revenues in FY 2006. Revenues from research services grew 52 percent to $22.7 million contributing 13 percent to operating revenues in FY 2006.

Kiran Mazumdar-Shaw, chairman and managing director said, “We will continue to invest in our discovery led research programs. The recent acquisition of the NOBEX portfolio has significantly enhanced our IP assets both in terms of patents as well as proprietary technologies that will play a key role in our innovation strategy for the future.”

She also said, “The year ahead is expected to see us entering the oncology market with our novel antibody product, BIOMAB-EGFR for the treatment of head and neck cancers. We believe our balanced portfolio of products and services will deliver superior shareholder value over the medium and long term. The year ahead will continue to be challenging due to uncertainties in market conditions and the impact of depreciation at our new facilities at Biocon Park.